Published on
March 26, 2025
In the media
BiotechTV interviews Peter Joyce (CEO & Co-founder)
About Greywolf Therapeutics
Greywolf Therapeutics is a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases.
The company’s first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly.
Greywolf’s oncology treatment (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating meaningful clinical activity. The company’s autoimmunity treatment (GRWD0715) is progressing in a Phase 1/2 trial to treat the source of axial spondyloarthritis ahead of a planned expansion into other autoimmune indications.
Greywolf is headquartered in Oxford, UK.
More information: Website | LinkedIn
Media enquiries
Patrick White, Head of Communications
